Q4 EPS Estimates for Envoy Medical Lowered by Analyst

Envoy Medical, Inc. (NASDAQ:COCH) – Analysts at Brookline Capital Management decreased their Q4 2024 earnings per share (EPS) estimates for Envoy Medical in a research report issued on Tuesday, November 19th. Brookline Capital Management analyst T. Bussian now anticipates that the company will post earnings of ($0.36) per share for the quarter, down from their previous estimate of ($0.29). Brookline Capital Management currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Envoy Medical’s current full-year earnings is ($1.07) per share. Brookline Capital Management also issued estimates for Envoy Medical’s Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.30) EPS and FY2025 earnings at ($1.39) EPS.

Separately, Ascendiant Capital Markets increased their price objective on Envoy Medical from $8.50 to $8.75 and gave the company a “buy” rating in a research note on Tuesday, September 3rd.

Envoy Medical Stock Performance

COCH opened at $2.18 on Friday. The stock’s 50 day simple moving average is $2.70 and its 200 day simple moving average is $2.64. Envoy Medical has a 1 year low of $1.01 and a 1 year high of $11.46.

Institutional Investors Weigh In On Envoy Medical

A hedge fund recently bought a new stake in Envoy Medical stock. Virtu Financial LLC purchased a new position in Envoy Medical, Inc. (NASDAQ:COCH) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 14,045 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 0.07% of Envoy Medical as of its most recent SEC filing. 8.59% of the stock is currently owned by hedge funds and other institutional investors.

Envoy Medical Company Profile

Envoy Medical, Inc, a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc in September 2023.